Accordingly, hyperinsulinemia maintained its immunosuppressive effect in CD4+ cells of the JAKi-treated patients by mitigating upregulation of the key Th1 transcription factors RORC and PRDM1, as well as the chemokine receptors CXCR3 and CCR5 (Figure 4A). The gene discussed is CXCR3; the disease is Hyperinsulinemia.